Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Non-Randomized, Controlled Study of the Effect of Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG) Versus Anti-Thymocyte Immunoglobulin (ATG) on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematologic Diseases

NCT06895538 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT06895538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06895538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Non-Randomized, Controlled Study of the Effect of Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG) Versus Anti-Thymocyte Immunoglobulin (ATG) on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematologic Diseases
Lead sponsor
Peking University First Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 3, 2025
Completion date
February 28, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma, mds